Mind Medicine (MindMed) Inc. (MNMD)
NASDAQ: MNMD · Real-Time Price · USD
7.16
+0.15 (2.07%)
Dec 20, 2024, 4:00 PM EST - Market closed
Mind Medicine (MindMed) Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for MNMD stock have an average target of 28.75, with a low estimate of 14 and a high estimate of 55. The average target predicts an increase of 301.54% from the current stock price of 7.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MNMD stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 4 | 5 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +179.33% | Dec 20, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $20 | Buy | Reiterates | $20 | +179.33% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +668.16% | Nov 11, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +95.53% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $35 → $55 | Strong Buy | Maintains | $35 → $55 | +668.16% | Aug 29, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.52
from -2.44
EPS Next Year
-1.46
from -1.52
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.40 | -1.38 | -1.23 | |||
| Avg | -1.52 | -1.46 | -1.61 | |||
| Low | -1.68 | -1.57 | -1.96 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.